Background
Methods
Bacterial isolates and drugs
Multilocus sequence typing (MLST)
Antimicrobial susceptibility testing and metallo-β-lactamase detection
Statistical analysis
Results
Summary of 42 A. baumannii isolates and MLST
Gender (%) | Age (%) | Hospital ward (%) | Type of specimen (%) | Inpatient status (%) |
---|---|---|---|---|
Male 30 (71.4%) | ≤17 0 (0%) | ICU 27 (64.3%) | Respiratory 35 (83.3%) | ≤2 days 4 (9.5%) |
Female 12 (28.6%) | 18-65 9 (21.4%) | Medical 10 (23.8%) | Blood 3 (7.1%) | 3-6 days 9 (21.4%) |
≥66 33 (78.6%) | Surgical 4 (9.5%) | Wound 2 (4.8%) | ≥7 days 29 (69.1%) | |
Burn 1 (2.4%) | Urine 1 (2.4%) | |||
CSF 1 (2.4%) |
Number of isolates | Specimens | Wards | gltA | gyrB | gdhB | recA | cpn60 | gpi | rpoD | ST |
---|---|---|---|---|---|---|---|---|---|---|
1 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
2 | Blood | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 5 | STn1 |
3 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
4 | Blood | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
5 | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
6 | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
7 | Sputum | Respiratory | 1 | 15 | 3 | 2 | 2 | 153 | 3 | ST457 |
8 | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
9 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
10 | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
11 | Sputum | Neurosurgery | 1 | 15 | 3 | 2 | 2 | 96 | 3 | STn2 |
12 | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
13 | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
14 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
15 | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
16 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
17 | Wound | Gastroenterology | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
18 | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
19 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
20 | Urine | Geriatrics ICU | 21 | 15 | 3 | 2 | 35 | 111 | 4 | ST254 |
21 | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
22 | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
23 | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
24 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
25 | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
26 | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
27 | Sputum | Neurosurgery | 1 | 81 | 3 | 2 | 2 | 96 | 4 | STn3 |
28 | Sputum | Respiratory | 21 | 15 | 3 | 2 | 35 | 111 | 4 | ST254 |
29 | Sputum | RICU | 21 | 15 | 3 | 2 | 35 | 111 | 4 | ST254 |
30 | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
31 | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
32 | Sputum | Neurosurgery | 1 | 81 | 3 | 2 | 2 | 96 | 4 | STn3 |
33 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
34 | BALF | RICU | 1 | 15 | 3 | 2 | 2 | 153 | 3 | ST457 |
35 | CSF | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
36 | Sputum | Respiratory | 21 | 15 | 3 | 2 | 35 | G1 | 3 | STn4 |
37 | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
38 | Wound | Burn | A1 | 15 | 3 | 2 | 2 | 153 | 4 | STn5 |
39 | Sputum | Geriatrics ICU | 21 | 15 | 3 | 2 | 35 | G1 | 3 | STn4 |
40 | Blood | Urinary surgery | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 |
41 | Sputum | Nephrology | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 |
42 | BALF | RICU | 11 | 65 | 3 | 20 | 37 | 96 | 15 | STn6 |
Antimicrobial susceptibility testing and metallo-β-lactamase detection
Isolate no. | SCF | TZP | CAZ | CRO | FEP | ATM | IPM | MEM | LEV | CIP | AK | DO | TGC | PB | TOB | Phenotype/MBL |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | R | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
2 | R | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
3 | R | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
4 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
5 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
6 | R | R | R | R | R | R | R | R | R | R | S | R | I | S | S | MDR/Neg |
7 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
8 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
9 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
10 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
11 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
12 | R | R | R | R | R | R | R | R | R | R | S | R | I | S | S | MDR/Neg |
13 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
14 | S | R | R | R | R | R | I | I | R | R | R | R | S | S | R | MDR/Neg |
15 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
16 | R | R | R | R | R | R | R | R | R | R | R | R | R | S | R | XDR/Neg |
17 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
18 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
19 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
20 | I | R | R | R | R | R | R | R | R | R | R | I | S | S | R | XDR/Neg |
21 | R | R | R | R | R | R | R | R | R | R | R | R | R | S | R | XDR/Neg |
22 | R | R | R | R | R | R | R | R | R | R | S | R | R | S | S | MDR/Neg |
23 | I | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
24 | S | R | R | R | R | R | S | S | R | R | S | R | I | S | S | MDR/Neg |
25 | R | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
26 | R | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
27 | R | R | R | R | R | R | S | I | R | R | R | R | I | S | R | MDR/Neg |
28 | I | R | R | R | R | R | R | R | R | R | R | R | S | S | R | XDR/Neg |
29 | I | R | R | R | R | R | R | R | R | R | R | I | S | S | R | XDR/Neg |
30 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
31 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
32 | I | R | R | R | I | R | S | S | R | R | R | I | I | S | R | MDR/Neg |
33 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
34 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
35 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
36 | I | R | R | R | R | I | R | R | R | R | R | S | S | S | R | MDR/Neg |
37 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
38 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
39 | R | R | R | R | R | R | R | R | R | R | R | I | S | S | R | XDR/Pos |
40 | R | R | R | R | R | R | R | R | R | R | R | R | I | S | R | XDR/Neg |
41 | I | R | R | R | R | R | S | I | R | R | R | R | R | S | R | MDR/Neg |
42 | I | S | R | R | R | R | S | S | I | R | R | I | R | S | R | MDR/Neg |
Susceptible (%) | 2.4 | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | 11.9 | 7.1 | 0.0 | 0.0 | 9.5 | 0.0 | 28.6 | 100.0 | 9.5 | - |
Compound/combination of compounds | MIC (μg/ml) | No. susceptible (%) | No. nonsusceptible (%)a
| Statistical analysisb
| |||
---|---|---|---|---|---|---|---|
MICRange
| MIC50
| MIC90
| χ2-values | P values | |||
AML | 40-320 | 80 | 160 | - | - | - | - |
IPM | 0.5-32 | 16 | 16 | 7 (16.7%) | 35 (83.3%) | - | - |
IPM +10 μg/ml AML | 0.5-32 | 8 | 16 | 13 (31.0%) | 29 (69.0%) | 2.363 | 0.200 |
IPM +20 μg/ml AML | 0.5-32 | 8 | 16 | 15 (35.7%) | 27 (64.3%) | 3.941 | 0.081 |
IPM +40 μg/ml AML | <0.5-32 | 4 | 16 | 23 (54.8%) | 19 (45.2%) | 13.274 | 0.001 |
Combination of compounds | FIC index (N,%) | ||||
---|---|---|---|---|---|
<0.5 Synergy | 0.5 to 0.75 partial synergy | 0.76 to 1.0 additive effect | >1.0 to 4.0 indifference | >4.0 antagonism | |
Imipenem + AML | 6 (14.3%) | 15 (35.7%) | 10 (23.8%) | 11 (26.2%) | 0 (0%) |